Abstract
This study analyzes 67 patients with small cell lung carcinoma (SCLC) treated with combined chemotherapy and radiotherapy at the National Kyushu Cancer Center. The overall response rate was 79% (37% CR, 42% PR). Survival outcomes were significantly better for patients with Limited Disease (LD) compared to Extensive Disease (ED), and for those receiving intensive alternating therapy versus mild concurrent therapy. The median survival time (MST) for the entire cohort was 8.5 months, but reached 19 months for LD patients who achieved a complete response (CR).
Introduction
Small Cell Lung Carcinoma (SCLC) is a highly aggressive malignancy known for rapid growth and early systemic spread. Historically, while radiotherapy provided local control, it failed to address distant metastases. Conversely, chemotherapy addressed systemic disease but often left local recurrences. This 1985 paper evaluates the efficacy of various combined-modality approaches to optimize survival by balancing local and systemic control.
Methods
A retrospective analysis was performed on 67 patients (60 males, 7 females; mean age 63) treated between 1972 and 1983. Patients were staged as having Limited Disease (LD, n=37) or Extensive Disease (ED, n=30). Treatment strategies evolved from "mild" concurrent chemotherapy (e.g., VEMT) and radiation to "intensive" alternating regimens (e.g., CAV or COM) and radiation. Survival was calculated using the Kaplan-Meier method, and responses were categorized as Complete Response (CR), Partial Response (PR), or No Change/Progressive Disease (NC/PD).
Results
The study found that disease extent was a primary determinant of survival. Patients with LD had a median survival time (MST) of 12 months, doubling the 6-month MST observed in ED patients (p < 0.00026).
Beyond disease staging, the quality of the initial response to treatment was the most critical prognostic factor. For the total cohort, those achieving a CR had an MST of 18 months, significantly outperforming those with a PR (8.5 months) or NC/PD (4 months).
The "intensive" alternating treatment group showed a marked advantage, with an MST of 17 months compared to 8 months in the "mild" group. The most favorable outcomes were seen in LD patients who achieved CR, where the MST reached 19 months and the 3-year survival rate was 23%.
Discussion and Limitations
While intensive therapy improved outcomes, local recurrence remained a challenge, occurring in nearly 30% of CR patients despite high-dose radiation. Toxicity, primarily leukopenia and mild radiation pneumonitis, was manageable. The study's retrospective nature and the small size of certain treatment subgroups are noted limitations. Future efforts should focus on optimizing the timing of radiotherapy and improving maintenance strategies to prevent late relapse.
Conclusion
Strategic combination of intensive chemotherapy and radiotherapy significantly improves survival in SCLC, particularly for patients with limited disease who achieve a complete response. These findings underscore the importance of dose intensity and disease staging in managing this aggressive cancer.
Reference: Hara, N., et al. (1985). Combination chemotherapy-radiotherapy of small cell carcinoma of the lung. Haigan (Lung Cancer), 25(2), 143-151.
Summary updated